U.S.-China trade truce triggers European share surge

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. WDAY
2. AAPL
3. JNJ
4. AMAT
5. META
6. NVDA
7. SPY
8. NRIX
9. SUNS
10. OIG

Go back to U.S.-China trade truce triggers European share surge

argenx (ARGX) Reports Detailed Data from Phase 2 Clinical Trial of Efgartigimod and Phase 1/2 Clinical Trial of Cusatuzumab

December 3, 2018 5:52 AM EST

argenx (NASDAQ: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it will share the detailed data from its Phase 2 clinical trial of efgartigimod (ARGX-113) in immune thrombocytopenia (ITP) and the Phase 1 portion of its Phase 1/2 clinical trial of cusatuzumab (ARGX-110) in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) during a workshop being held in conjunction with the 60th American Society of Hematology (ASH) Annual Meeting and Exposition.

The workshop is... More